|
||
| |||||||
|
|
Keele, UK, 16th November 2005 –
Cobra Biomanufacturing Plc (London Stock Exchange AIM) announced that it
has strengthened its senior management team.
Martin Comberbach PhD, Director of GMP Manufacturing
Operations, comes from a pharmaceutical process and project engineering
background having held senior positions at GSK’s Rixensart vaccine
facility, Metris Therapeutics Ltd, and more recently as Director of Global
Manufacturing for GeneMedix Plc.
Paul Stockbridge PhD, Director of Quality, has over
25 years experience in the pharmaceutical / biotechnology industry. After
23 years with Eli Lilly in the UK he moved to Aventis Pharma in 2002 where
he was Head of Quality Operations at their Holmes Chapel (UK) site. He is
registered as a Qualified Person under the Permanent Provisions of the EU
directives, bringing our number of QPs to three, and is highly experienced
in interacting with many inspectional bodies including the FDA and the
MHRA.
Following 12 years with Cobra, most recently as
European Director of Business Development, Tony Mulcahy PhD has been
promoted to the new role of Director of Customer Relations with global
responsibility for contract management and marketing functions.
Dr David Thatcher, CEO of Cobra commented, “We are
delighted that Paul and Martin have joined Cobra to further strengthen our
GMP production services. Together with Tony’s promotion, this
demonstrates Cobra’s total commitment to quality and customer service as
key drivers of our business. Since listing on AIM in 2002 Cobra has
established itself as a global leader in biopharmaceuticals manufacture.
These appointments add considerable strength to our senior management team
as we prepare for our next phase of growth.”
About Cobra Biomanufacturing Plc:
Cobra Biomanufacturing Plc is a leading
international manufacturer of biopharmaceuticals to the life science
industry. Founded in 1992, Cobra provides innovative manufacturing
solutions to the biopharmaceutical industry covering DNA, virus, cellular
therapeutics and recombinant protein products.
Cobra was the first company to develop and gain GMP
(Good Manufacturing Practice) standard DNA manufacture in Europe, with
specific expertise in DNA medicines. A range of unique, patented
technologies, underpins this revenue generating business.
Cobra floated on the Alternative Investment Market
of the London Stock Exchange in June 2002 raising £7 million and raised a
further £5.2 million in May 2003 in order to further expand capacity in
Oxford UK.
Cobra is committed to conducting its manufacturing
activities in accordance with appropriate current Good Manufacturing
Practice (cGMP) and Good Control Laboratory Practice (GCLP) regulations
and/or guidelines. The MHRA has granted a “Manufacturer’s Authorization
for Investigational Medicinal Products” under the Directive 2001/20/EC and
applies to booth the Keele and Oxford facilities.
www.cobrabio.com
For further information please contact:
Cobra Biomanufacturing
Plc
David
Thatcher, Chief Executive Officer,
Tel: + 44 (0) 1782 714181
Northbank Communications
Marc Egelhofer, Tel: 44 (0) 1260 296 500
|
| ||||||||||
|
